Search

Spirometric small airway obstruction is associated with impaired ventilatory response to exercise independently of FEV 1 /FVC ratio https://bit.ly/3pre4sk., Competing Interests: Conflict of interest: B. Knox-Brown has nothing to disclose. Conflict of interest: K. Sylvester has nothing to disclose. Conflict of interest: A.F.S. Amaral has nothing to disclose., (Copyright ©The authors 2023.)

Background: Small airways obstruction (SAO) is a key feature of both COPD and asthma, which have been associated with workplace exposures. Whether SAO, which may occur early in the development of obstructive lung disease and without symptoms, also associates with occupational exposures is unknown., Methods: Using UK Biobank data, we derived measurements of SAO from the 65 145 participants with high-quality spirometry and lifetime occupational histories. The ALOHA+ Job Exposure Matrix was used to assign lifetime occupational exposures to each participant. The association between SAO and lifetime occupational exposures was evaluated using a logistic regression model adjusted for potential confounders. A second logistic regression model was also run to account for potential co-exposures., Results: SAO was present in varying proportions of the population depending on definition used: 5.6% (forced expiratory flow between 25 and 75% of the forced vital capacity (FEF 25-75 ) < lower limit of normal (LLN)) and 21.4% (forced expiratory volume in 3 s (FEV 3 )/forced expiratory volume in 6 s (FEV 6 ) 3 /FEV 6 3 /FEV 6 3 /FEV 6

Although there are many health benefits from being active, there was no benefit observed in this study from vigorous physical activity in reducing the risk of asthma onset in middle-aged adults https://bit.ly/3bEtHDn., Competing Interests: Conflict of interest: M.A. Russell has nothing to disclose. Conflict of interest: S. Dharmage has nothing to disclose. Conflict of interest: E. Fuertes has nothing to disclose. Conflict of interest: A. Marcon has nothing to disclose. Conflict of interest: A-E. Carsin has nothing to disclose. Conflict of interest: S. Pascual Erquicia has nothing to disclose. Conflict of interest: J. Heinrich has nothing to disclose. Conflict of interest: A. Johannessen has nothing to disclose. Conflict of interest: M.J. Abramson has nothing to disclose. Conflict of interest: A.F.S. Amaral has nothing to disclose. Conflict of interest: I. Cerveri has nothing to disclose. Conflict of interest: P. Demoly reports board fees from Chiesi, IQVIA, Ménarini and Sanofi; board and speaker bureau fees from AstraZeneca, Bausch & Lomb and ThermoFisher Scientific; and speaker fees from Mylan and Novartis, all outside the submitted work. Conflict of interest: V. Garcia-Larsen has nothing to disclose. Conflict of interest: D. Jarvis has nothing to disclose. Conflict of interest: J. Martinez-Moratalla has nothing to disclose. Conflict of interest: D. Nowak has nothing to disclose. Conflict of interest: L. Palacios-Gómez has nothing to disclose. Conflict of interest: G. Squillacioti has nothing to disclose. Conflict of interest: W. Raza has nothing to disclose. Conflict of interest: M. Emtner has nothing to disclose. Conflict of interest: J. Garcia-Aymerich has nothing to disclose., (Copyright ©The authors 2021.)

At the European Respiratory Society's International Congress of 2019, which was held in Madrid, Spain, there were several sessions with exciting poster and oral presentations within the fields of epidemiology and tobacco control. This article is the summary of two of these sessions. One was on the use of Big Data in epidemiology and the other, on the global burden of respiratory disease and tobacco., Competing Interests: Conflict of interest: M. Jankowski has nothing to disclose. Conflict of interest: A.F.S. Amaral works in the same group as two of the speakers (D. Jarvis and P. Burney) whose talks are commented on., (Copyright ©ERS 2020.)

In this article, early career members and experienced members of the Epidemiology and Environment Assembly of the European Respiratory Society highlight and summarise a selection of six sessions from the Society's annual congress, which in 2018 was held in Paris, France. The topics covered in these sessions span from cutting-edge molecular epidemiology of lung function to clinical, occupational and environmental epidemiology of respiratory disease, and from emergent tobacco products to tobacco control., Competing Interests: Conflict of interest: M. de Vries has nothing to disclose. Conflict of interest: E.L. Axson has nothing to disclose. Conflict of interest: J. Ratanachina has nothing to disclose. Conflict of interest: O. Dumas has nothing to disclose. Conflict of interest: S. De Matteis has nothing to disclose. Conflict of interest: A. Bédard reports ERS Young Scientist sponsorship and an ERS Long Term Fellowship (LTRF 2015-5838), outside the submitted work. Conflict of interest: C. Roda reports grants from the European Commission/European Respiratory Society outside the submitted work. Conflict of interest: S. Moitra reports a Long Term Research Fellowship (LTRF 201701-0088) from the European Respiratory Society, ERS Young Scientist 2018 sponsorship, an editorial honorarium from Lancet Respiratory Medicine, faculty remuneration from the European Respiratory Society, an editorial honorarium from Current Respiratory Medicine Reviews and a nonfinancial honorarium from Oxford Publications, outside the submitted work. Conflict of interest: E. Dagli has nothing to disclose. Conflict of interest: A. Dimanti has nothing to disclose. Conflict of interest: A.G. Dilektasli has nothing to disclose. Conflict of interest: S. Ravara has nothing to disclose. Conflict of interest: A.F.S. Amaral has nothing to disclose.